Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV ActivityAnita Mathias, Brian P. Kearney, James Hoi Po Hui et al.|Clinical Pharmacology & Therapeutics|2009Cited by 208
Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical TrialAndrew Zolopa, Andrew Cheng, Steven L. Chuck et al.|The Journal of Infectious Diseases|2010Cited by 114
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionCalvin Cohen, Brian P. Kearney, Richard Elion et al.|AIDS|2011Cited by 109
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infectionRichard Elion, David R. Warren, Calvin Cohen et al.|AIDS|2011Cited by 92